Navigation Links
FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
Date:1/2/2012

s on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production -- both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com http://www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the FDA and/or the EMA, that accelerated approval by the FDA of pixantrone may not occur, that CTI may not be able to address satisfactorily the two key matters raised by the ON
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Malaria discovery gives hope for new drugs and vaccines
3. Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs
4. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
5. UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs
6. Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
7. Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs
8. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
9. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
10. Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
11. Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 BioStructures, LLC, ... has hit a milestone of 4,000 implantations of ... 510(k) cleared in early 2014 as a bone ... spine fusion procedures.  This is a distinguished status ... than 6% of new synthetic products have received ...
(Date:7/28/2015)...  Faced with increasing challenges such as costly ... symptomatic, the global healthcare industry today is gradually ... curing or significantly changing the course of a ... regenerative medicine as a viable alternative. ... health with the potential to resolve unmet medical ...
(Date:7/27/2015)... ... , ... Production of high tenacity filament yarn of viscose rayon (excluding sewing ... instance, it surpassed the EUR 106 million mark (in value terms) in 2013, while ... major producer, while Italy is a key consumer. , The high tenacity filament ...
(Date:7/27/2015)... FORT WORTH, Texas , July 27, 2015 ... Biopreservation Media Market by Type (Home-brew Media, Pre-formulated Media), by ... North America , Europe , ... & Forecast to 2019", The global biopreservation media market was ... grow to around $571.5 million by 2019, at a CAGR ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3
... 6, 2012 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Officer of Neurocrine Biosciences, will be presenting at the 14th ... The live presentation takes place on Monday, February ... Time.  The presentation will be webcast and may be accessed ...
... 6, 2012  BioStorage Technologies, a global provider of ... chain logistics for the bioscience industry, will host ... in Clinical Trials on Tuesday, March 6, 2012 ... The 2-hour workshop will focus ...
... 2012 UV Flu Technologies, Inc. ( OTCBB: ... ahead of schedule in its continuing program to eliminate all debt. ... the remaining and final convertible note, in the amount of $32,500 ... we have made in the last twelve months is nothing short ...
Cached Biology Technology:BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... TORONTO, ON Psychologists at the University of ... interaction has the ability to influence an individual,s sensitivity ... clinical implications for doctor-patient relationships and the general well-being ... of studies over the past several decades have demonstrated ...
... CHICAGO --- Northwestern Medicine researchers at the Robert H. ... a new, nontoxic drug made from a chemical in soy ... to the rest of the body. These findings will ... Research Frontiers in Cancer Prevention Research Conference. Genistein, a ...
... at the University of California, San Diego School of ... of federally approved drugs to more than 1,000 proteins ... opening new avenues to repurpose these drugs to treat ... PLoS Computational Biology . "Tuberculosis is currently ...
Cached Biology News:Psychologists identify influence of social interaction on sensitivity to physical pain 2Soy may stop prostate cancer spread 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2
... DeStreak Reagent, 1 ml. Improves ... gels by preventing streaking.Eliminates extra ... of proteins.Stabilizes proteins throughout entire ... well-resolved protein patterns.Ideal for both ...
LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
SlowFade Antifade Kit with DAPI...
Mouse Collagen IV...
Biology Products: